Merck
Advisory Services
The Situation
When Spain and Portugal joined the European Union, neither country provided product patents for medicines. The treaties of accession therefore restricted exports of these medicines to other Member States, but only for a limited period of time.
NERA's Role
NERA modeled the potential losses to our client, Merck, and to other research-based manufacturers and estimated the impact that these losses could have on future R&D and hence flow of new medicines.
